Expert Ratings For Gilead Sciences

Expert Ratings For Gilead Sciences

Analysts have provided the following estimates for Gilead Sciences (NASDAQ:GILD) for the most recent quarter.

Trending. An entrepreneur makes $175,000 a year selling T-shirts he never touches, working just an hour a day;

Must read. Mark Cuban says it's the key to "controlling your own destiny" and making big bucks

bullish pretty intense Indifferent a bit irrelevant Carry
overall ratings 1: 2: 6:00 a.m 0: 0:
last 30 days 0: 0: 1: 0: 0:
1 million ago 0: 0: 0: 0: 0:
2 months ago 1: 0: 1: 0: 0:
3 months ago 0: 2: 4: 0: 0:

Based on 9 analysts providing 12-month price targets over the last 3 months, Gilead Sciences has an average price target of $92.33, with a high of $112.00 and a low of $80.00.

Below is a summary of how these 9 analysts rated Gilead Sciences over the last 3 months. The higher the number of ratings, the more analysts rate the stock positively, and the higher the number of downgrades, the more analysts rate the stock negatively.

price target chart © Provided by Benzinga Target price chart

This current average is 5.32% above the previous average price target of $87.67.

Stay informed with Gilead Sciences analyst notes.

Ratings are derived from banking and financial systems analysts or professionals reporting on specific securities or specific sectors (usually quarterly for each security). Analysts typically get their information from company conference calls and meetings, financial reports, and discussions with people important to their decision-making.

Some analysts also offer forecasts for utility metrics such as earnings, revenue, and growth estimates to provide further guidance on what to do with specific metrics. It's important to note that while stock and industry analysts are experts, they are human and can only guess their opinions to traders.

See also  'Great Honor': Berkeley Lab Scientists Elected To American Academy Of Arts, Sciences

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Latest GILD ratings

Date: Business Action: starting For
March 2022 barley holds underweight
March 2022 RBC capital holds Overcome
February 2022 BMO capital: sale Overcome market trend

See additional analyst notes on GILD

Check out the latest analyst ratings

This article on Gilead Sciences Expert Reviews originally appeared on


Fundamental Analysis Amgen Vs GlaxoSmithKline vs Gilead | The Best Pharma Stocks to BUY | AMGN GSK GOLD

Leave a Comment